- $106.34bn
- $123.47bn
- €46.72bn
FDA drug center head expected to leave after commissioner's exit, sources say
Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports
Brief: Sanofi Supports AlphaDetect To Accelerate Detection Of Alpha-1
Brief: Sanofi Asks To Pull Diabetes Drug Out Of FDA Voucher Program After Political Appointee Interfered With Review - Stat News
French and Benelux stocks-Factors to watch
Brief: Sanofi Invests $294M To Expand AI Center Of Excellence In Toronto
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Regeneron beats quarterly estimates on strong Dupixent demand (updated)
Regeneron beats quarterly results estimates on strong Dupixent demand
Brief: Sanofi successfully prices 2.3 billion euros of bond issues
Brief: Sanofi's Cenrifki Recommended For EU Approval Against Secondary Progressive Multiple Sclerosis Without Relapses
Europe risks falling further behind in medicine race, warns Roche CEO
European shares muted as investors assess Mideast developments, corporate earnings
Sanofi shares boosted by Q1 beat helped by Dupixent sales
Sanofi's first quarter earnings edges past estimates ahead of CEO change (updated)
Brief: Sanofi Q1 Business Operating Income Beats Vara Consensus
France's Sanofi Q1 revenue rises 13.6% on strong Dupixent sales
Brief: Sanofi Q1 Net Income EUR 1,614 Million